Pharmacokinetics and bioavailability of digitoxin by a specific assay

R. T. MacFarland, F. I. Marcus, Paul E Fenster, P. E. Graves, D. Perrier

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites. After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days. After oral administration, the elimination half-life was 5.8 days. The bioavailability was 81.5% using the specific assay. Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0%. Assay of aqueous fractions from extracted serum samples indicated higher levels of water-soluble metabolites following oral compared to intravenous digitoxin administration. These findings suggest that previously reported values for digitoxin bioavailability using non-specific methods may be falsely elevated due to the presence of digitoxin metabolites in serum.

Original languageEnglish (US)
Pages (from-to)85-89
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Volume27
Issue number1
DOIs
StatePublished - Jan 1984

Fingerprint

Digitoxin
Biological Availability
Pharmacokinetics
Intravenous Administration
Half-Life
Serum
Radioimmunoassay
Oral Administration
Water

Keywords

  • bioavailability
  • digitoxin
  • digitoxin metabolites
  • pharmacokinetics
  • radioimmunoassay

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Pharmacokinetics and bioavailability of digitoxin by a specific assay. / MacFarland, R. T.; Marcus, F. I.; Fenster, Paul E; Graves, P. E.; Perrier, D.

In: European Journal of Clinical Pharmacology, Vol. 27, No. 1, 01.1984, p. 85-89.

Research output: Contribution to journalArticle

MacFarland, R. T. ; Marcus, F. I. ; Fenster, Paul E ; Graves, P. E. ; Perrier, D. / Pharmacokinetics and bioavailability of digitoxin by a specific assay. In: European Journal of Clinical Pharmacology. 1984 ; Vol. 27, No. 1. pp. 85-89.
@article{bc9be3ed56834af8a011d89f051eb12e,
title = "Pharmacokinetics and bioavailability of digitoxin by a specific assay",
abstract = "The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites. After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days. After oral administration, the elimination half-life was 5.8 days. The bioavailability was 81.5{\%} using the specific assay. Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0{\%}. Assay of aqueous fractions from extracted serum samples indicated higher levels of water-soluble metabolites following oral compared to intravenous digitoxin administration. These findings suggest that previously reported values for digitoxin bioavailability using non-specific methods may be falsely elevated due to the presence of digitoxin metabolites in serum.",
keywords = "bioavailability, digitoxin, digitoxin metabolites, pharmacokinetics, radioimmunoassay",
author = "MacFarland, {R. T.} and Marcus, {F. I.} and Fenster, {Paul E} and Graves, {P. E.} and D. Perrier",
year = "1984",
month = "1",
doi = "10.1007/BF00553160",
language = "English (US)",
volume = "27",
pages = "85--89",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics and bioavailability of digitoxin by a specific assay

AU - MacFarland, R. T.

AU - Marcus, F. I.

AU - Fenster, Paul E

AU - Graves, P. E.

AU - Perrier, D.

PY - 1984/1

Y1 - 1984/1

N2 - The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites. After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days. After oral administration, the elimination half-life was 5.8 days. The bioavailability was 81.5% using the specific assay. Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0%. Assay of aqueous fractions from extracted serum samples indicated higher levels of water-soluble metabolites following oral compared to intravenous digitoxin administration. These findings suggest that previously reported values for digitoxin bioavailability using non-specific methods may be falsely elevated due to the presence of digitoxin metabolites in serum.

AB - The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites. After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days. After oral administration, the elimination half-life was 5.8 days. The bioavailability was 81.5% using the specific assay. Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0%. Assay of aqueous fractions from extracted serum samples indicated higher levels of water-soluble metabolites following oral compared to intravenous digitoxin administration. These findings suggest that previously reported values for digitoxin bioavailability using non-specific methods may be falsely elevated due to the presence of digitoxin metabolites in serum.

KW - bioavailability

KW - digitoxin

KW - digitoxin metabolites

KW - pharmacokinetics

KW - radioimmunoassay

UR - http://www.scopus.com/inward/record.url?scp=0021163994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021163994&partnerID=8YFLogxK

U2 - 10.1007/BF00553160

DO - 10.1007/BF00553160

M3 - Article

C2 - 6489430

AN - SCOPUS:0021163994

VL - 27

SP - 85

EP - 89

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -